First Time Disclosures from Rome

The highly anticipated First Time Disclosures session, attended by over 400 conferees, both in-person and virtually, was organized by the MEDI Division of ACS at the ACS Fall 2024 meeting in Denver. This session unveiled 13 fascinating small molecules currently in clinical development. The two-part event showcased innovations ranging from Novartis’ pentafluorosulfanyl-containing antimalarial, IWY357, to Vividion’s covalent activator of KEAP1, which targets NRF2 degradation. This article captures the essence of the session, providing the structures and targets of the novel molecules disclosed.

The "New Drugs on the Horizon" sessions at the AACR Annual Meeting 2024 in San Diego revealed twelve innovative oncology agents and offered attendees a first look at their structures and preliminary data as they enter/progress in the clinic. In case you missed any of these exciting compounds – including selective CDK inhibitors, molecular glues, bifunctional degraders, a radiopharmaceutical, a bifunctional antibody, and an ADC – this article covers the structures and targets disclosed. A separate session disclosed the structure of a pan-RAS isoform inhibitor with remarkable clinical results.

The highly anticipated First Time Disclosures session at the ACS Spring 2024 Meeting in New Orleans, organized by Nicole Goodwin and H. Rachel Lagiakos, presented a variety of new orally available small molecules. In case you missed any of these exciting molecules, from Oric’s CD73 inhibitor to Deciphera’s first-in-class ULK1/2 inhibitor, this article provides the structures and targets for the novel molecules disclosed at the session.